University of Exeter Medical School

Dr Anne-Marie Russell ATSF

Dr Anne-Marie Russell ATSF

Senior Lecturer & Senior Clinical Fellow

 A.Russell4@exeter.ac.uk

 South Cloisters 

 

South Cloisters, University of Exeter, St Luke's Campus, Heavitree Road, Exeter, EX1 2LU, UK

Overview

Research Focus:  Patient reported measures including patient centred outcomes (PCO) and experience measures (PREMs), using patient-centred and mixed methodological approaches. My special interest in interstitial lung diseases (ILDs) originated in the Dyspnea-12 study, 2008 and strengthend through collaboration on the PROFILE study (NCT01134822), a national longitudinal observational study to assess potential biomarkers to predict outcomes for people with Idiopathic Pulmonary Fibrosis (IPF).

Awarded a competitive NIHR CDRF in 2012 I completed a part time PhD at Imperial College developing and testing a patient-reported outcome measure for patients with IPF (IPF-PROM © Imperial College London). The 12-item IPF-PROM has been validated in UK, Europe and US IPF populations; it has been translated into Danish, German, Spanish and Portuguese. Website in development - ifpprom.com check back for updates

I work collaboratively nationally and internationally in the ILD specialism and locally lead a Supporting Self-management in ILD research group supporting research associates, research fellows and interns working on range of projects relating to ILD. 

Funded through NHSE I retain clinical expertise as a senior clinical fellow in the SW peninsular specialist commissioned ILD service. I am seconded (0.4wte) to the NIHR West England CRN where I have a regional and national leadership role, working closely with the NIHR NMO, to build research capability and capacity for NMAHPS.

See Research tab for further information and supervision offered.

Qualifications

  • PhD Respiratory Medicine | Imperial College London

  • MSc (distinction) | Advanced Practice & Clinical Research 
  • BSc (hons) Public Health | Brunel University 
  • BSc (hons) Professional practice and research methods
  • Post Graduate Certificate in Education (distinction) 
  • Post Graduate Certificate in Family Therapy & Systemic Practice
  • Certificate in Tropical Diseases and Laboratory Techniques | LSHTM

Career

Whilst retaining an honrorary contract at the University of Exeter effective as of 1st Janaury 2024 I am relocating to take up a position as Chair at the University of Birmingham, College of Medical & Dental Sciences.

Links

Research group links

Back to top

Research

Research interests

I am a mixed methods researcher with experience of consensus approaches and psychometrics. I collaborate on studies relating to fibrotic lung conditions including all interstitial lung disease entities, patient-centeredness and supported self-managment. I maintain interest in caregiver burden and non-pharmacological approaches to palliation of symptoms with a core focus on measuring what matters to patients so that outcomes and experiences, particularly PROMs and PREMs are authentic and meaningful.

Patient-centred approaches include working with patients as research partners from conception through to study design, delivery and co-authorship of outputs.  I am an active member of the University of Exeter Patients in Collaboration for pulmonary fibrosis research group (EPIC) who guide collective and interdisciplinary research endeavours, and with external patient partners.

http://orcid.org/0000-0002-0468-353

I offer pre-doctoral, doctoral and post-doctoral supervision

Current projects include:

Lizzie Grillo: 'The Physiotherapy Assessment of Breathing Pattern Dysfunction' (NIHR CDRF)

Carita Bramhill: 'Living beyond a diagnosis of idiopathic Pulmonary Fibrosis: A mixed method exploration of patient related experience and unmet healthcare needs' (Ussher scholarship)

Malik Althobiani : 'Home monitoring of physiology and symptoms to detect Interstitial Lung Disease exacerbations and progression'

Adine Adonis : 'Optimising measurement of progression and wellbeing of people with HTLV Associated Myelopathy and Asymptomatic Carriers' (NIHR PCAF)

Jessica Mandizha & Dr Joe Lanario: 'Qualitative exploration of experiences of home-monitoring in peolpe living with Interstitial Lung Disease' (NIHR CRN SWP)

Research projects

Active Studies as Co-investigator 

  • Research Council, NIHR, British Academy & Royal Society MRC CiC | Aug 2022 £26k
  • Project: Diagnosis and disease monitoring of chronic lung disease with novel digital acoustic technologies - £26k (co-applicant). University of Exeter.
  • NHSx Digital Health Partnership Award Oct 2021 - £196k.
  • Project: Respiratory remote monitoring programme Royal Devon & Exeter NHS Trust & Guy’s & St Thomas’ NHS Foundation Trust. Co-applicant
  • NIHR & UKRI July 2020 - £630K
  • Project:The development, testing and evaluation of a COVID-19 fundamental nursing care protocol ISRCTN 13177364 (co-applicant). University of Exeter.
  • RCF (RD&E) award March 2021 - £14.5k
  • Project:  STARSHIP I: Study of Telomeres and Role of Sex Hormones in Pulmonary Fibrosis Stage I (Feasibility) PI: Anna Duckworth. University of Exeter.

International 

  • Co-investigator (2020): Validation of the Mawdsley Questionnaire in Systemic Sclerosis-associated calcinosis. Tulane University | New Orleans. (Recruiting) PI: LA Saketkoo
  • Co-investigator: (2019) Compassion Cultivation Skills Training (CCT) in Medicine: Controlled Skill-building Intervention Trial in Pulmonary Critical Care (PCC) Fellows. Louisiana State University | New Orleans. (in evaluation) PI: LA Saketkoo

Studies now Closed

  • Chief-Investigator: (2019) An observational study to explore the validity and appropriateness of the generic Patient Activation Measure (PAM) in a population diagnosed with Interstitial Lung Disease. Imperial Health Charity / PF Trust UK  / London. £59k
  • Co-investigator: (2018/9) An open label phase IV, multicentre, international, interventional study to evaluate the effect of diet on gastrointestinal adverse events in patients with IPF treated with Pirfenidone (MADIET) Sponsor: Biomedical Research Institute, Barcelona 
  • Co-investigator: (2016/18) Development and Testing of a Patient Reported Experience Measure in Idiopathic Pulmonary Fibrosis (IPF-PREM study) utilising patient centred and mixed methodologies. Imperial college healthcare NHS Trust. 
  • Co-investigator / UK CI : (2015/16) Observational study of the effect of Pirfenidone on cough in patients with idiopathic pulmonary fibrosis. Sponsor: ERASMUS / Netherlands
  • Chief Investigator: (2013/18) Development; Testing & Validation of a Patient Reported Outcome measure in Idiopathic Pulmonary Fibrosis (IPF-PROM study). Multicentre. Sponsor Imperial College NIHR CDRF £240k
  • Research Associate: (2010/16) A prospective, UK multicentre, observational idiopathic pulmonary fibrosis cohort study (PROFILE): Royal Brompton & Harefield NHS Trust: NCT01110694 

Research grants

  • 2021 NIHR
    NIHR Clinical Research Network South West Peninsula
  • 2021 NHS
    Research Capacity Funding
  • 2020 NIHR
    National Institute for Health Research (NIHR) and UK Research and Innovation (UKRI)

Back to top

Publications

Journal articles

Picts A, Russell A-M (In Press). From healthcare professional to degree apprentice. Clinical Teacher
Bramhill C, Langan D, Mulryan H, Eustace-Cook J, Russell A-M, Brady A-M (2024). A scoping review of the unmet needs of patients diagnosed with idiopathic pulmonary fibrosis (IPF). PLoS One, 19(2). Abstract.  Author URL.
Holland AE, Spathis A, Marsaa K, Bausewein C, Ahmadi Z, Burge AT, Pascoe A, Gadowski AM, Collis P, Jelen T, et al (2024). European Respiratory Society Clinical Practice Guideline on symptom management for adults with serious respiratory illness. Eur Respir J Abstract.  Author URL.
Richards DA, Bollen J, Jones B, Melendez-Torres GJ, Hulme C, Cockcroft E, Cook H, Cooper J, Creanor S, Cruickshank S, et al (2024). Evaluation of a COVID-19 fundamental nursing care guideline versus usual care: the COVID-NURSE cluster randomized controlled trial. J Adv Nurs, 80(5), 2137-2152. Abstract.  Author URL.
Althobiani MA, Ranjan Y, Russell AM, Jacob J, Orini M, Sankesara H, Conde P, Rashid Z, Dobson RJB, Hurst JR, et al (2024). Home monitoring to detect progression of interstitial lung disease: a prospective cohort study. Respirology, 29(6), 513-517.
Althobiani MA, Russell AM, Jacob J, Ranjan Y, Folarin AA, Hurst JR, Porter JC (2024). Interstitial lung disease: a review of classification, etiology, epidemiology, clinical diagnosis, pharmacological and non-pharmacological treatment. Frontiers in Medicine, 11 Abstract.
Wells M, Harding S, Dixon G, Buckley K, Russell A-M, Barratt SL (2024). Patient and caregiver shared experiences of pulmonary fibrosis (PF): a systematic literature review. Respir Med, 227 Abstract.  Author URL.
Mostard R, Russell A-M (2023). Casting light on the many facets of Sarcoidosis. Current Opinion in Pulmonary Medicine, 29, 475-477.
Visca D, Centis R, Pontali E, Zampogna E, Russell A-M, Migliori GB, Andrejak C, Aro M, Bayram H, Berkani K, et al (2023). Clinical standards for diagnosis, treatment and prevention of post-COVID-19 lung disease. International Journal of Tuberculosis and Lung Disease, 27 (10), 729-741. Abstract.
King C, Shlobin OA, Spagnolo P, Cottin V, Mostard RLM, Russell AM (2023). Editorial introductions. Current Opinion in Pulmonary Medicine, 29(5), VII-IX.
Bramhill C, Langan D, Mulryan H, Eustace-Cook J, Russell A-M, Brady A-M (2023). Exploration of the unmet needs of patients diagnosed with idiopathic pulmonary fibrosis: a scoping review protocol. BMJ Open, 13(5), e070513-e070513. Abstract.
Molina-Molina M, Shull J, Vicens V, Rivera Ortega P, Antoniou K, Bonella F, Russell A-M, Renzoni, E, Maher T, Vancheri A, et al (2023). Gastrointestinal pirfenidone adverse events in IPF depending on diet: MADIET clinical trial. European Respiratory Journal, 62
Saketkoo LA, Valenzuela A, International Myositis Assessment and Clinical Studies Group IMACS, Calcinosis Scientific Interest Group CSIG, Chung L, Orandi A, Alexanderson H, Dimachkie M, Ernste F, Fligelstone K, et al (2023). Moving Forward Together: Collaborative Landscapes of Research in Idiopathic Inflammatory Myopathies and Calcinosis. Rheumatology, kead 331
Mandizha J, Lanario J, Duckworth A, Lines S, Pavia A, Elworthy V, Muraleedharan V, Jorge Da Ponte A, Shuttleworth R, Brown G, et al (2023). Patient Perspectives on Home-Spirometry in Interstitial Lung Disease: a qualitative co-designed study. British medical journal Abstract.
Adonis A, Russell A-M, Diallo H, Preston M, Shields A, Strachan S, Young S, Ashford S, Cassidy E, Taylor G, et al (2023). Patient research priority setting partnership in Human T-Cell Lymphotropic Virus Type 1. Health Expectations Abstract.
Saketkoo LA, Patterson KC, Russell A-M (2023). Pause for thought: navigating the complex scientific domains of fatigue and of mindfulness-based practices in sarcoidosis and beyond. The Lancet Respiratory Medicine, 11(3), 219-220.
Saketkoo LA, Russell A-M, Patterson K, Obi ON, Drent M (2023). Sarcoidosis and Frailty: Recognizing Factors that Foster Holistic Resilience. Current Opinion in Pulmonary Medicine, 29, 501-511. Abstract.
Althobiani M, Shuttleworth R, Conway J, Dainton J, Duckworth A, Jorge Da Ponte A, Mandizha J, Lanario J, Gibbons M, Lines S, et al (2023). Supporting self-management for patients with Interstitial Lung Diseases: Utility and acceptability of digital devices. PLOS Digital Health, 2(12) Abstract.
Grillo L, Russell A-M, Shannon H, Lewis A (2023). The Physiotherapy Assessment of Breathing Pattern Disorder: a Qualitative evaluation. BMJ Open, 10 Abstract.
Khor Y, Cottin V, Holland A, Inoue Y, McDonald V, Oldam J, Renzoni E, Russell A-M, Strek M, Ryerson C, et al (2023). Treatable traits: a comprehensive precision medicine in interstitial lung disease. European respiratory journal, ERJ-00404-2023.R2 Abstract.
Saketkoo LA, Obi ON, Patterson KC, Russell A-M (2022). Ageing with Interstitial lung disease: preserving health and well being. Curr Opin Pulm Med, 28(4), 321-336. Abstract.  Author URL.
Bonella F, Wuyts WA, Vancheri C, Russell AM, Lievens D, Stansen W, Wijsenbeek MS (2022). Effects of nintedanib in patients with idiopathic pulmonary fibrosis and varying severities of cough. Pneumologie, 76, s20-s21.
Antoniou KM, Vasarmidi E, Russell A-M, Andrejak C, Crestani B, Delcroix M, Dinh-Xuan AT, Poletti V, Sverzellati N, Vitacca M, et al (2022). European Respiratory Society statement on long COVID follow-up. European Respiratory Journal, 60(2), 2102174-2102174. Abstract.
Whear R, Abbott RA, Bethel A, Richards DA, Garside R, Cockcroft E, Iles-Smith H, Logan PA, Rafferty AM, Shepherd M, et al (2022). Impact of COVID-19 and other infectious conditions requiring isolation on the provision of and adaptations to fundamental nursing care in hospital in terms of overall patient experience, care quality, functional ability, and treatment outcomes: systematic review. Journal of Advanced Nursing, 78(1), 78-108. Abstract.
Sugg HVR, Richards DA, Russell A, Burnett S, Cockcroft EJ, Thompson Coon J, Cruickshank S, Doris FE, Hunt HA, Iles‐Smith H, et al (2022). Nurses’ strategies for overcoming barriers to fundamental nursing care in patients with <scp>COVID</scp>‐19 caused by infection with the <scp>SARS‐COV</scp>‐2 virus: Results from the ‘<scp>COVID‐NURSE</scp>’ survey. Journal of Advanced Nursing, 79(3), 1003-1017. Abstract.
Gilbert A, Homer V, Brock K, Korsgen S, Geh I, Hill J, Gill T, Hainsworth P, Tutton M, Khan J, et al (2022). Quality-of-life outcomes in older patients with early-stage rectal cancer receiving organ-preserving treatment with hypofractionated short-course radiotherapy followed by transanal endoscopic microsurgery (TREC): non-randomised registry of patients unsuitable for total mesorectal excision. Lancet Healthy Longev, 3(12), e825-e838. Abstract.  Author URL.
Saketkoo LA, Jensen K, Nikoletou D, Newton JJ, Rivera FJ, Howie M, Reese RK, Goodman M, Hart PB, Bembry W, et al (2022). Sarcoidosis Illuminations on Living During COVID-19: Patient Experiences of Diagnosis, Management, and Survival Before and During the Pandemic. J Patient Exp, 9 Abstract.  Author URL.
Ndili O, Saketkoo LA, Russell A-M, Baughman RP (2022). Sarcoidosis: Updates on therapeutic drug trials and novel treatment approaches. Frontiers in Medicine, 9
Cahalan R, Russell AM, Meade C, Hayes G (2022). SingStrong – singing for better lung health in pulmonary fibrosis: a feasibility study. Physiotherapy Practice and Research, 43(1), 17-25. Abstract.
Saketkoo LA, Escorpizo R, Varga J, Keen KJ, Fligelstone K, Birring SS, Alexanderson H, Pettersson H, Chaudhry HA, Poole JL, et al (2022). World Health Organization (WHO) International Classification of Functioning, Disability and Health (ICF) Core Set Development for Interstitial Lung Disease. Frontiers in Pharmacology, 13
Saketkoo LA, Escorpizo R, Varga J, Keen KJ, Fligelstone K, Birring SS, Alexanderson H, Pettersson H, Chaudhry HA, Poole J, et al (2022). World Health Organization (WHO) International Classification of Functioning, Disability and Health (ICF) Core Set Development for Interstitial Lung Disease: a Collaboration with the Global Fellowship on Rehabilitation and Exercise in Systemic Sclerosis (G-FoRSS). Journal Frontiers in Pharmacology Abstract.
Saketkoo LA, Frech T, Varjú C, Domsic R, Farrell J, Gordon JK, Mihai C, Sandorfi N, Shapiro L, Poole J, et al (2021). A comprehensive framework for navigating patient care in systemic sclerosis: a global response to the need for improving the practice of diagnostic and preventive strategies in SSc. Best Practice & Research Clinical Rheumatology, 35(3), 101707-101707.
Richards DA, Sugg HVR, Cockcroft E, Cooper J, Cruickshank S, Doris F, Hulme C, Logan P, Iles-Smith H, Melendez-Torres GJ, et al (2021). COVID-NURSE: evaluation of a fundamental nursing care protocol compared with care as usual on experience of care for noninvasively ventilated patients in hospital with the SARS-CoV-2 virus—protocol for a cluster randomised controlled trial. BMJ Open, 11(5), e046436-e046436. Abstract.
Adams RA, Fisher DJ, Graham J, Seligmann JF, Seymour M, Kaplan R, Yates E, Parmar M, Richman SD, Quirke P, et al (2021). Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial. J Clin Oncol, 39(33), 3693-3704. Abstract.  Author URL.
Wijsenbeek MS, Bonella F, Orsatti L, Russell A-M, Valenzuela C, Wuyts WA, Baile WF (2021). Communicating with patients with idiopathic pulmonary fibrosis: can we do it better?. ERJ Open Research, 8(1), 00422-2021. Abstract.
Pettersson H, Alexanderson H, Poole JL, Varga J, Regardt M, Russell A-M, Salam Y, Jensen K, Mansour J, Frech T, et al (2021). Exercise as a multi-modal disease-modifying medicine in systemic sclerosis: an introduction by the Global Fellowship on Rehabilitation and Exercise in Systemic Sclerosis (G-FoRSS). Best Pract Res Clin Rheumatol, 35(3). Abstract.  Author URL.
Cassidy N, Fox L, Love M, Byrne I, Doyle AM, Korn B, Shanagher D, Shone T, Cullen M, Cullen T, et al (2021). Fibrotic interstitial lung disease - palliative care needs: a World-Café qualitative study. BMJ Supportive & Palliative Care Abstract.
Sugg HVR, Russell A-M, Morgan L, Iles-Smith H, Richards DA, Morley N, Burnett S, Cockcroft E, Thompson Coon J, Cruickshank S, et al (2021). Fundamental nursing care in patients with the SARS-CoV-2 virus: results from the ‘COVID-NURSE’ mixed methods survey into nurses’ experiences of missed care and barriers to care. BMC Nursing, 20
Saketkoo LA, Russell A-M, Jensen K, Mandizha J, Tavee J, Newton J, Rivera F, Howie M, Reese R, Goodman M, et al (2021). Health-Related Quality of Life (HRQoL) in Sarcoidosis: Diagnosis, Management, and Health Outcomes. Diagnostics, 11(6), 1089-1089. Abstract.
Althobiani MA, Evans RA, Alqahtani JS, Aldhahir AM, Russell A-M, Hurst JR, Porter JC (2021). Home monitoring of physiology and symptoms to detect interstitial lung disease exacerbations and progression: a systematic review. ERJ Open Research, 7(4), 00441-2021. Abstract.
Noth I, Cottin V, Chaudhuri N, Corte TJ, Johannson KA, Wijsenbeek M, Jouneau S, Michael A, Quaresma M, Rohr KB, et al (2021). Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial. European Respiratory Journal, 58(1), 2001518-2001518. Abstract.
Seligmann JF, Fisher DJ, Brown LC, Adams RA, Graham J, Quirke P, Richman SD, Butler R, Domingo E, Blake A, et al (2021). Inhibition of WEE1 is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: a Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) with Active Monitoring. J Clin Oncol, 39(33), 3705-3715. Abstract.  Author URL.
Shuttleworth R, Nancarrow T, Wollteron R, White M, Lines S, Mandizha J, Duckworth A, Russell A, Gibbons M, Scotton C, et al (2021). P144 Red cell distribution width (RDW) and neutrophil lymphocyte ratio (NLR) as prognostic markers in idiopathic pulmonary fibrosis (IPF). Thorax, 76(Suppl 2), a145-a146.
Aronson KI, Danoff SK, Russell A-M, Ryerson CJ, Suzuki A, Wijsenbeek MS, Bajwah S, Bianchi P, Corte TJ, Lee JS, et al (2021). Patient-centered Outcomes Research in Interstitial Lung Disease: an Official American Thoracic Society Research Statement. Am J Respir Crit Care Med, 204(2), e3-e23. Abstract.  Author URL.
Althobiani M, Alqahtani JS, Hurst JR, Russell A-M, Porter J (2021). Telehealth for patients with interstitial lung diseases (ILD): results of an international survey of clinicians. BMJ Open Respiratory Research, 8(1), e001088-e001088. Abstract.
Burki TK (2021). The importance of patient-reported outcomes and measures. The Lancet Respiratory Medicine, 9(11), 1218-1220.
Castro-Sanchez E, Russell A-M, Dolman L, Wells M (2021). What place does nurse‐led research have in the COVID‐19 pandemic?. International Nursing Review, 1-5.
Seligman WH, Fialho L, Sillett N, Nielsen C, Baloch FM, Collis P, Demedts IKM, Fleck MP, Floriani MA, Gabriel LEK, et al (2021). Which outcomes are most important to measure in patients with COVID-19 and how and when should these be measured? Development of an international standard set of outcomes measures for clinical use in patients with COVID-19: a report of the International Consortium for Health Outcomes Measurement (ICHOM) COVID-19 Working Group. BMJ Open, 11(11), e051065-e051065. Abstract.
Saketkoo LA, Alexanderson H, Lammi MR, LeSage D, Jensen K, Scholand MB, Volkmann ER, Russell AM (2020). An ode to the primal tonic of dance—congratulating the Life of Breath project. The Lancet Respiratory Medicine, 8(12), e90-e91.
Kim JW, Olive S, Jones S, Thillai M, Russell A-M, Johnson MJ, Wilson A (2020). Interstitial lung disease and specialist palliative care access: a healthcare professionals survey. BMJ Supportive & Palliative Care, 12(e6), e748-e751. Abstract.
Russell A (2020). Letter from the <scp>UK</scp>. Respirology, 25(12), 1325-1327. Abstract.
Drake TM, Docherty AB, Harrison EM, Quint JK, Adamali H, Agnew S, Babu S, Barber CM, Barratt S, Bendstrup E, et al (2020). Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. American Journal of Respiratory and Critical Care Medicine, 202(12), 1656-1665.
Saketkoo LA, Scholand MB, Lammi MR, Russell A-M (2020). Patient-reported outcome measures in systemic sclerosis–related interstitial lung disease for clinical practice and clinical trials. Journal of Scleroderma and Related Disorders, 5(2_suppl), 48-60. Abstract.
Edwards C, Costello E, Cassidy N, Vick B, Russell A-M (2020). The utility of an electronic health journal with home spirometry in a real world population of people with fibrotic lung conditions. Journal of Medical Internet Research, 8
Edwards C, Costello E, Cassidy N, Vick B, Russell A-M (2020). Use of the patientMpower App with Home-Based Spirometry to Monitor the Symptoms and Impact of Fibrotic Lung Conditions: Longitudinal Observational Study. JMIR mHealth and uHealth, 8(11), e16158-e16158. Abstract.
Moor CC, Wijsenbeek MS, Balestro E, Biondini D, Bondue B, Cottin V, Flewett R, Galvin L, Jones S, Molina-Molina M, et al (2019). Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey. ERJ Open Research, 5(4), 00124-2019. Abstract.
Lim RK, Humphreys C, Morisset J, Holland AE, Johannson KA (2019). Oxygen in patients with fibrotic interstitial lung disease: an international Delphi survey. European Respiratory Journal, 54(2), 1900421-1900421. Abstract.
Russell AM, Olive S, Lines S, Murphy A, Hocking J, Newell K, Morris H, Harris E, Dixon C, Agnew S, et al (2018). Contemporary challenges for specialist nursing in interstitial lung disease. Breathe, 14(1), 36-41. Abstract.
Visca D, Mori L, Tsipouri V, Fleming S, Firouzi A, Bonini M, Pavitt MJ, Alfieri V, Canu S, Bonifazi M, et al (2018). Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial. Lancet Respir Med, 6(10), 759-770. Abstract.  Author URL.
Saketkoo LA, Karpinski A, Young J, Adell R, Walker M, Hennebury T, Wickremasinghe M, Russell A-M (2018). Feasibility, utility and symptom impact of modified mindfulness training in sarcoidosis. ERJ Open Research, 4(2), 00085-2017.
Newell K, Smith K, Russell A-M (2018). Palliative and end of life care in idiopathic pulmonary fibrosis. Primary Health Care, 28(4), 27-35.
Maher TM, Oballa E, Simpson JK, Porte J, Habgood A, Fahy WA, Flynn A, Molyneaux PL, Braybrooke R, Divyateja H, et al (2017). An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. The Lancet Respiratory Medicine, 5(12), 946-955. Abstract.
Spruit MA, Burtin C, Langer D, Makonga J, Russell A-M, York J, Steenbruggen I (2017). Assembly 9: allied respiratory professionals. Breathe, 12(4), e113-e114.
van Manen MJG, Birring SS, Vancheri C, Vindigni V, Renzoni E, Russell A-M, Wapenaar M, Cottin V, Wijsenbeek MS (2017). Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis. EUROPEAN RESPIRATORY JOURNAL, 50(4).  Author URL.
Kreuter M, Bendstrup E, Russell A-M, Bajwah S, Lindell K, Adir Y, Brown CE, Calligaro G, Cassidy N, Corte TJ, et al (2017). Palliative care in interstitial lung disease: living well. LANCET RESPIRATORY MEDICINE, 5(12), 968-980.  Author URL.
Maher TM, Molina-Molina M, Russell A-M, Bonella F, Jouneau S, Ripamonti E, Axmann J, Vancheri C (2017). Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries. BMC PULMONARY MEDICINE, 17  Author URL.
van Manen MJG, Birring SS, Vancheri C, Cottin V, Renzoni EA, Russell A-M, Wijsenbeek MS (2016). Cough in idiopathic pulmonary fibrosis. EUROPEAN RESPIRATORY REVIEW, 25(141), 278-286.  Author URL.
Russell A-M, Maher TM (2016). Daily Home Spirometry: a New Milestone in the Field of Pulmonary Fibrosis Reply. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 194(8), 1034-1035.  Author URL.
Russell A-M, Adamali H, Molyneaux PL, Lukey PT, Marshall RP, Renzoni EA, Wells AU, Maher TM (2016). Daily Home Spirometry: an Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 194(8), 989-997.  Author URL.
Russell A-M, Ripamonti E, Vancheri C (2016). Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients' perspectives of the disease and treatment. BMC PULMONARY MEDICINE, 16  Author URL.
Lewis A, Cave P, Stern M, Welch L, Taylor K, Russell J, Doyle A-M, Russell A-M, McKee H, Clift S, et al (2016). Singing for Lung Health-a systematic review of the literature and consensus statement. NPJ PRIMARY CARE RESPIRATORY MEDICINE, 26  Author URL.
Russell A-M, Swigris JJ (2016). What's it like to live with idiopathic pulmonary fibrosis? Ask the experts. EUROPEAN RESPIRATORY JOURNAL, 47(5), 1324-1326.  Author URL.
Russell AM (2015). Care planning in idiopathic pulmonary fibrosis. Nursing Times, 111(18), 20-22. Abstract.
Russell A-M (2015). Idiopathic pulmonary fibrosis: Care Standards. Nursing Times, 111:18, 23-25.
Russell AM (2015). Interstitial pulmonary fibrosis: Care standards. Nursing Times, 111(18), 16-17. Abstract.
Jenkins RG, Simpson JK, Saini G, Bentley JH, Russell A-M, Braybrooke R, Molyneaux PL, McKeever TM, Wells AU, Flynn A, et al (2015). Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. LANCET RESPIRATORY MEDICINE, 3(6), 462-472.  Author URL.
Lammi M, Baughman R, Birring S, Russell A-M, Ryu J, Scholand M, Distler O, LeSage D, Sarver C, Antoniou K, et al (2015). Outcome Measures for Clinical Trials in Interstitial Lung Diseases. Current Respiratory Medicine Reviews, 11(2), 163-174.
Russell A-M, Sprangers MAG, Wibberley S, Snell N, Rose DM, Swigris JJ (2015). The need for patient-centred clinical research in idiopathic pulmonary fibrosis. BMC MEDICINE, 13  Author URL.
Russell AM, Maher TM (2014). Detecting anxiety and depression in patients diagnosed with an interstitial lung disease. Can we do better?. RESPIROLOGY, 19(8), 1095-1096.  Author URL.
Wuyts WA, Peccatori FA, Russell A-M (2014). Patient-centred management in idiopathic pulmonary fibrosis: similar themes in three communication models. European Respiratory Review, 23(132), 231-238.
Molyneaux PL, Cox MJ, Willis-Owen SAG, Mallia P, Russell KE, Russell A-M, Murphy E, Johnston SL, Schwartz DA, Wells AU, et al (2014). The Role of Bacteria in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 190(8), 906-913.
Stock CJ, Sato H, Fonseca C, Banya WAS, Molyneaux PL, Adamali H, Russell A-M, Denton CP, Abraham DJ, Hansell DM, et al (2013). Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. THORAX, 68(5), 436-441.  Author URL.
Adamali HI, Anwar MS, Russell A-M, Egan JJ (2012). Non-pharmacological treatment of idiopathic pulmonary fibrosis. Current Respiratory Care Reports, 1(4), 208-215.
Yorke J, Swigris J, Russell A-M, Moosavi SH, Kwong GNM, Longshaw M, Jones PW (2011). Dyspnea-12 is a Valid and Reliable Measure of Breathlessness in Patients with Interstitial Lung Disease. CHEST, 139(1), 159-164.  Author URL.
Yorke J, Russell AM (2008). Interpreting the language of breathlessness. Nursing times, 104(23), 36-39. Abstract.

Chapters

Saketkoo LA, Gordon JK, Fligelstone K, Mawdsely A, Chaudhry H, Valenzuela A, Christensen A, Khalique SM, Jensen K, Weinmann SC, et al (2023). Patient Experience of Systemic Sclerosis related Calcinosis: an International Study Informing Clinical Trials, Practice and the Development of the Mawdsley Calcinosis Questionnaire. In Weisman MH, Frech TM (Eds.) Sclerodoma: Best Approaches to Patient Care, Philadelphia: Elsevier, 463-481.
Russell AM, Saketkoo LA (2021). Patient-Centredness and Patient-Reported Measures (PRMs) in Palliation of Lung Disease. In  (Ed) Palliative Care in Lung Disease, Springer Nature, 43-75.
Russell A-M (2016). Assessing Anxiety and Depression. In Preston W (Ed) Respiratory Nursing at a Glance, Chichester, Sussex: John Wiley & Sons, 46-47. Abstract.
Russell A-M (2016). Interstitial Lung Disease. In Preston W, Kelly C (Eds.) Respiratory Nursing at a Glance, Chichester, Sussex: John Wiley & Sons, 68-69. Abstract.
Russell A-M (2016). Sarcoidosis. In Preston W, Kelly C (Eds.) Respiratory Nursing at a Glance, Chichester Sussex: John Wiley & Sons, 70-71. Abstract.

Conferences

Duckworth A, Prague JK, Norris KT, Emms H, Sayers R, Steward M, Thould H, Savill A, Lines S, Mandizha J, et al (2024). Starship: Study of Telomeres and Role of Sex Hormones in Pulmonary Fibrosis. American Thoracic Society 2024 International Conference, May 17-22, 2024 - San Diego, CA.
Mandizha J, Lanario J, Duckworth A, Lines S, Paiva AR, Elworthy V, Muraleedharan V, Brown G, Cosby M, Russell A, et al (2023). Interstitial Lung Disease (ILD): Longitudinal exploration of patient experiences of home spirometry. Nurses.
Duckworth A, Prague J, Wood A, Lunnon K, Lindsay M, Russell A, Gibbons M, Tyrrell J, Scotton C (2023). S97 Heritable risk in pulmonary fibrosis: Study of disease penetrance amongst carriers of damaging rare variants. ‘Scar tissue’- Pathogenesis of lung fibrosis.
Adonis A, Russell A-M, Cassidy E, Asford S, Taylor G (2022). Defining research priorities for people living with HTLV-1 through patient/public involvement and engagement (PPIE) workshops. 2022 International Virtual Conference on Human Retrovirology: HTLV 2022. 8th - 11th May 2022. Abstract.
Fabbri L, Wright L, Jones S, Cowan K, Russell A-M, Hart S, Gibbons M, Chaudhuri N, Lynch-Wilson J, Jenkins G, et al (2022). Defining stakeholders’ research priorities in progressive pulmonary fibrosis in the United Kingdom. European Respiratory Society Conference. 4th - 6th Sep 2022. Abstract.
Shuttleworth R, Althobiani M, Duckworth A, Conway J, Dainton J, Mandizha J, Lines S, Jorge Da Ponte A, Scotton C, Gibbons M, et al (2022). Digital device usage for home-monitoring in interstitial lung disease [ILD]:mixed-method survey. European Respiratory Society Congress. 4th - 6th Sep 2022.
Crestani B, Wyuts WA, Vancheri C, Bonella F, Russell A-M, Lievens D, Stansen W, Wijsenbeek M (2022). Effets du nintédanib chez des patients atteints de fibrose pulmonaire idiopathique et présentant des sévérités variables de toux. 26e CONGRÈS DE PNEUMOLOGIE DE LANGUE FRANÇAISE. 21st - 23rd Jan 2022. Abstract.
Mandizha J, Gibbons M, Lines S, Brown G, Ana Jorge Da Ponte A, Duckworth A, Shuttleworth R, Scotton C, Russell A, Crosby M, et al (2022). Experiences of home-monitoring in patients with Interstitial Lung Disease (ILD): an exploratory, qualitative study. European Respiratory Society Congress. 4th - 6th Sep 2022.
Mandizha J, Duckworth A, Almond H, Brown G, Lines S, Jorge Da Ponte, A, Shuttleworth R, Lanario J, Seward M, Sayers R, et al (2022). Modification of the Rheumatoid Arthritis (RA) Patient Reported Experience Measure (PREM) for patients with Interstitial Lung Disease (ILD). European Respiratory Society Congress 2022. 4th - 6th Sep 2022. Abstract.
Grillo L, Lewis A, Shannon H, Russell A-M (2022). PHYSIOTHERAPISTS’ OPINIONS OF THE PHYSIOTHERAPY ASSESSMENT OF BREATHING PATTERN DYSFUNCTION: a QUALITATIVE STUDY. British Thoracic Society Winter Metting 2022. 23rd - 25th Nov 2022. Abstract.
Fabbri L, Cowan K, Adams W, Conway J, Jones S, Wright L, Chaudhuri N, Russell A-M, Gibbons M, Hart S, et al (2022). PROGRESSIVE PULMONARY FIBROSIS: TOP TEN RESEARCH PRIORITIES. British Thoracic Society winter Meeting 2022. 23rd - 25th Nov 2022. Abstract.
Valenzuela A, Russell A-M, Chung L, Jensen K, Saketkoo LA (2022). Test-retest Reliability for the Mawdsley Calcinosis Questionnaire for the Measurement of Calcinosis Burden in Patients with Systemic Sclerosis. ACR Convergence 2022. 10th - 14th Nov 2022. Abstract.
Wuyts WA, Vancheri C, Bonella F, Russell A, Lievens D, Stansen W, Wijsenbeek MS (2021). Effects of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Varying Severities of Cough.  Author URL.
Althobiani M, Hurst J, Russell A, Porter J (2021). P6 Telehealth for patients with interstitial lung diseases (ILD): results of an international survey of clinicians. British Thoracic Society Winter Meeting 2021 Online, Wednesday 24 to Friday 26 November 2021, Programme and Abstracts.
Cassidy N, Judge E, O'Dowd G, Shone T, Russell A-M (2021). The Irish Lung Fibrosis Association's Multi-Stakeholder World Cafe on Pulmonary Fibrosis Services in Ireland During Covid-19 and Beyond.  Author URL.
Fox L, McLeodl L, Russell A, Edwards C, O'Reilly KMA (2020). An Observational Study of Self-Monitoring of Spirometry and Symptoms via a Mobile Electronic Health Journal in Usual Care of Patients with Idiopathic Pulmonary Fibrosis.  Author URL.
Koschel D, Maher T, Cottin V, Russell A, Corte T, Hammerl P, Michael A, Rohr K, Quaresma M, Stowasser S, et al (2020). Correlation between home and clinic spirometry in subjects with IPF: results from the INMARK trial. 61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.
Russell A, Wickremasinghe M, Aul R, Datta A, Saketkoo L, Wells M (2020). Measuring Patient Activation Measurement in Patients Diagnosed with Interstitial Lung Disease (ILD) to Inform Enabling and Compassionate Care.  Author URL.
Russell A-M, Aul R, Datta A, Wickremasinghe M (2020). Measuring patient activation in an interstitial lung disease (ILD) population: an exploratory study. ERS International Congress 2020 abstracts.
Fontanilles E, Vancheri C, Wijsenbeek M, Antoniou K, Rivera P, Bonella F, Renzoni E, Anne-Marie A-M, Vicens-Zygmunt V, Suarez-Cuartin G, et al (2020). Monounsaturated Fatty Acid diet associates less gastrointestinal adverse events of pirfenidone: phase IV clinical trial. ERS International Congress 2020 abstracts.
Fox L, Mcleod L, Russell A-M, Edwards C, O'Reilly K (2020). Single-arm observational study of a mobile app + home spirometry in idiopathic pulmonary fibrosis. ERS International Congress 2020 abstracts.
Russell A, Shone A, Love M, Shanagher D, Byrne I, Fox L, Korn B, Doyle A, Cassidy N (2019). A World Cafe Approach to Palliative Care and Planning for the Future in Fibrotic Lung Disease.  Author URL.
Maher T, Cottin V, Russell A-M, Corte T, Hammerl P, Michael A, Rohr KB, Quaresma M, Stowasser S, Noth I, et al (2019). Correlation between home and clinic spirometry in subjects with IPF: results from the INMARK trial.  Author URL.
Russell A-M, Datta A, Newell K, Jones S, Conway J, Saktkoo LA, Wickremasinghe M (2019). Development of a patient reported experience measure (PREM) for idiopathic pulmonary fibrosis (IPF).  Author URL.
van Manen MJG, Birring SS, Vancheri C, Odink AE, Hussain B, Vindigni V, Renzoni E, Russell A-M, Wapenaar M, Cottin V, et al (2019). Predictors of objective cough in patients with idiopathic pulmonary fibrosis (IPF).  Author URL.
Cassidy N, O'Dowd G, McGowan M, Shone T, Russell A-M (2018). Evaluation of a World Cafe Forum on Palliative Care and Planning for the Future.  Author URL.
Fleming S, Firouzi A, Farquhar M, Tsipouri V, Visca D, Mori L, Canu S, Hogben CR, Kokosi M, Kouranos V, et al (2018). Experiences of Supplemental Ambulatory Oxygen for Patients with Fibrotic Lung Disease: Qualitative Evidence from the Mixed Method AmbOx Trial.  Author URL.
Walsh S, Cahill T, Edwards C, Costello E, Walsh J, Russell A, O'Regan AW (2018). Patient-Reported Monitoring of Symptoms and Spirometry Via the patientMpower Platform in Idiopathic Pulmonary Fibrosis.  Author URL.
Russell A, Wickremasinghe M, Saketkoo L, Borril Z, Fletcher S, Adamali HI, Wells AU, Maher TM, Renzoni EA, Fleming S, et al (2018). Preliminary Testing of the Idiopathic Pulmonary Fibrosis Patient Reported Outcome Measure (IPF PRoM).  Author URL.
Russell AM, Wickremasinghe M, Renzoni E, Adamali H, Borril Z, Fletcher S, Maher TM, Kwong GNM, Saketkoo LA, Fleming S, et al (2018). THE IDIOPATHIC PULMONARY FIBROSIS PATIENTS REPORTED OUTCOME MEASURE (IPF-PROM) IS RELIABLE AND VALID FOR USE IN POPULATIONS WITH IPF.  Author URL.
Edwards C, Cassidy N, Costello E, Russell A-M (2017). A longitudinal approach to supported self-management: sustainability of the idiopathic interstitial pneumonia (IIP) electronic health journal (patientMpower) with integrated home spirometry.  Author URL.
Edwards C, Cassidy N, Costello E, Russell A-M (2017). A longitudinal approach to supported self-management: sustainability of the idiopathic interstitial pneumonia (IIP) electronic health journal (patientMpower) with integrated home spirometry.  Author URL.
Visca D, Mori L, Tsipouri V, Canu S, Bonini M, Pavitt M, Fleming S, Firouzi A, Farquhar M, Leung E, et al (2017). AmbOx trial: does ambulatory oxygen improve quality of life in patients with fibrotic interstitial lung disease?.  Author URL.
Visca D, Mori L, Tsipouri V, Canu S, Bonini M, Pavitt M, Fleming S, Firouzi A, Farquhar M, Leung E, et al (2017). Ambox: a Randomised Controlled, Crossover Trial Evaluating the Effects of Ambulatory Oxygen on Health Status in Patients with Fibrotic Interstitial Lung Disease.  Author URL.
Russell A-M, Jones G, Saketkoo L, Doyle A-M, Sanderson T, D'Accord C, Adamali H, Borrill Z, Fletcher S, Wickremasinghe M, et al (2017). Development and Preliminary Testing of the Idiopathic Pulmonary Fibrosis Patient Reported Outcome Measure (ipf-Prom): Uk and Ireland Multi-Centre Study.  Author URL.
Mori L, Canu S, Visca D, Tsipouri V, Bonini M, Pavitt M, Fleming S, Firouzi A, Farquhar M, Leung E, et al (2017). PREDICTORS OF UPTAKE OF AMBULATORY OXYGEN ON COMPLETION OF THE AMBOX TRIAL, a STUDY TO ASSESS EFFECTS OF AMBULATORY OXYGEN ON QUALITY OF LIFE IN PATIENTS WITH FIBROTIC INTERSTITIAL LUNG DISEASE.  Author URL.
Russell A-M, Cave P, Taylor K, Lewis A, Hopkinson NS, Wells AU (2017). Rhythm and song: Breath management in Idiopathic Interstitial Pneumonias (IIP's). Pilot study.  Author URL.
Russell AM, Sonecha S, Datta A, Hewitt R, Howell I, Elliott A, Wickremasinghe M (2016). DEVELOPMENT OF PATIENT REPORTED EXPERIENCE MEASURE (PREM) FOR IDIOPATHIC PULMONARY FIBROSIS (IPF).  Author URL.
Hogben C, Renzoni E, Wells AU, Kokosi M, Chua F, Maher TM, Russell AM (2016). Development of pre-admission information for referrals with suspected interstitial lung disease to a specialist unit.  Author URL.
Russell A-M, Johnston KN, Yorke J, Williams MT (2016). Differences in Perceptual Experiences of Breathlessness and Impairment Between People with Moderate-Severe COPD in Australia and the United Kingdom.  Author URL.
Russell A-M, Johnston KN, Yorke J, Williams MT (2016). Dyspnoea-12 Scores Reported "these Days" Are Greater Than Those Reported "today": Differences in People with COPD, Asthma and Ild.  Author URL.
Russell A-M, Jones G, Sabella R, Cassidy N, Burge G, Lines S, Stanley L, Fletcher S, Weallans M, Bray M, et al (2016). Health status & impact of living with idiopathic pulmonary fibrosis (IPF): UK & Ireland Delphi survey.  Author URL.
Russell A-M, Scholand M, Snyder EA, Russell A, Burdett C, Doyle A-M, Lasky J, Renzoni E, Wells A, Saketkoo L, et al (2016). Impact, Survival, Symptoms and Management: Us and Uk Patient Perceptions of Living with Idiopathic Pulmonary Fibrosis.  Author URL.
Stock C, Bonini M, Kingston S, Lindahl GE, Russell A-M, Molyneaux PL, Saunders P, Kokosi MA, Sestini P, Wells AU, et al (2016). Muc5b and Tollip Variants: Association with Disease Progression and Survival in an Ipf Cohort.  Author URL.
Saketkoo L, Young J, Adell R, Karpinski AC, Walker M, Russell A-M (2016). Perceptions of a Modified Mindfulness Training (mt) Program in Sarcoidosis.  Author URL.
Visca D, Fleming S, Firouzi A, Farquhar M, Hopkinson N, Hogben C, Banya W, Cullinan P, De Lauretis A, Kokosi M, et al (2016). Randomised controlled, crossover trial to evaluate the effects of ambulatory oxygen on health status in patients with fibrotic lung disease.  Author URL.
Russell A-M, Scholand M, Snyder EA, Doyle A-M, Russell A, Burdett C, Lasky J, Saketkoo LA (2016). Trajectory of Symptom Burden, Impact and Survival in an Idiopathic Pulmonary Fibrosis Population.  Author URL.
Maher TM, Molina-Molina M, Russell A-M, Bonella F, Jouneau S, Ripamonti E, Axmann J, Vancheri C (2016). UNMET NEEDS IN THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (IPF) - INSIGHTS FROM PATIENT CHART REVIEW IN FIVE EUROPEAN COUNTRIES.  Author URL.
Russell A-M, Doyle A-M, Burdett C, Gane J, Aden Z, Fleming S, Cullinan P (2015). A patient centred approach to the development of a patient reported outcome measure (PRoM) in idiopathic pulmonary fibrosis (IPF).  Author URL.
Russell A-M, Doyle A, Fleming S, Burdett C, Ross D, Aden Z, Maher TM, Cullinan P (2015). Development of a Patient Reported Outcome Measure ( prom) in Idiopathic Pulmonary Fibrosis (ipf): Incorporating a Research Partnership with Patients.  Author URL.
Russell A-M, Sanderson T, Wells AU, Fleming S, Maher TM, Cullinan P (2015). Development of a Patient Reported Outcome Measure (prom) in Idiopathic Pulmonary Fibrosis (ipf): an Iterative Process.  Author URL.
Saketkoo LA, Escorpizo R, Keen KJ, Fligelstone K, Birring SS, Lammi MR, Lasky JA, LeSage DR, Renzoni E, Russell AM, et al (2015). INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY, AND HEALTH (ICF) CORE SETS FOR CONNECTIVE TISSUE DISEASE INTERSTITIAL LUNG DISEASE (CTD-ILD) AND IDIOPATHIC PULMONARY FIBROSIS (IPF) - a NECESSARY MAP TO HEALTH CARE PROVISION IN THE ERA OF ICD-11.  Author URL.
Russell A-M, Sanderson T, Fleming S, Wells A, Maher T, Cullinan P (2015). Item generation for a patient reported outcome measure (PRoM) in idiopathic pulmonary fibrosis (IPF): Application of consensus methods.  Author URL.
Russell AM, Doyle AM, Ross D, Burdett C, Gane J, Fleming S, Aden Z, Maher TM, Cullinan P (2015). PATIENT AND CARER CO-INVESTIGATORS: SHARED EXPERIENCES OF a RESEARCH STEERING GROUP FROM THE IDIOPATHIC PULMONARY FIBROSIS PATIENT REPORTED OUTCOME MEASURE (IPF-PROM) STUDY.  Author URL.
Cove J, Russell AM, Wright J, Hogben C, Kokosi M, Mak V, Chua F, Wells A, Doyle AM, Renzoni E, et al (2015). PILOT STUDY TO TEST THE FEASIBILITY OF a PSYCHOLOGICAL SUPPORT WORKSHOP FOR PATIENTS NEWLY DIAGNOSED WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) AND THEIR FAMILIES.  Author URL.
Doyle A-M, Burdett C, Gane J, Aden Z, Russell A-M (2015). Psychological distress in UK patients with idiopathic pulmonary fibrosis; use of emotion thermometers interpreted within a biopsychosocial constructionist framework.  Author URL.
Saketkoo L, Escorpizo R, Keen KJ, Fligelstone K, Lammi MR, LeSage D, Russell A-M, Birring SS, Sarver C, Varga J, et al (2015). The World Health Organization (who) International Classification of Functioning, Disability, and Health (icf) Core Sets for Connective Tissue Disease Interstitial Lung Disease (ctd-Ild) and Idiopathic Pulmonary Fibrosis (ipf) - a Necessary Map to Health Care Provision in the Era of Icd-11.  Author URL.
Russell AM, Sanderson T, Fleming S, Wells AU, Maher TMM, Cullinan TP (2014). DEVELOPMENT OF AN IDIOPATHIC PULMONARY FIBROSIS (IPF) PATIENT REPORTED OUTCOME MEASURE (PROM): AN ITERATIVE APPROACH TO ITEM GENERATION.  Author URL.
Escorpizo R, Keen KJ, Fligelstone K, Lammi MR, LeSage D, Russell A-M, Birring S, Sarver C, Varga J, Distler O, et al (2014). International Classification of Functioning, Disability, and Health (ICF) Core Sets for Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) and Idiopathic Pulmonary Fibrosis (IPF) - a Necessary Map to Health Care Provision in the Era of ICD-11.  Author URL.
Russell AM, Vancheri C, Maronati M, Giot C (2013). A QUALITATIVE EUROPEAN SURVEY OF PATIENTS PERCEPTIONS OF CURRENT MANAGEMENT OF IDIOPATHIC PULMONARY FIBROSIS.  Author URL.
Russell A-M, Fraser U, Molyneaux P, Wells A, Renzoni E, Lukey P, Maher T (2013). Quality of life measures in patients with idiopathic pulmonary fibrosis.  Author URL.
Russell A-M, Molyneaux PL, Wells AU, Renzoni E, Luley P, Maher TM (2013). Symptom Measures in Patients with Idiopathic Pulmonary Fibrosis.  Author URL.
Russell A-M, Molyneaux PL, Lukey PT, Fraser UH, Renzoni EA, Wells A, Maher TM (2012). Daily Hand-Held Spirometry for the Monitoring of Patients with Idiopathic Pulmonary Fibrosis. American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California.
Russell A-M, Molyneaux PL, Adamali HI, Fraser UH, Lukey PT, Wells A, Maher T (2012). Symptom Related Quality of Life Measures in Patients with Idiopathic Pulmonary Fibrosis. American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California.
Adamali HI, Delgado CM, Stock C, Lindhal GE, Molyneaux P, Russell A-M, Wells A, Renzoni EA, Maher T (2012). Telomere (TL) shortening is associated with disease severity in scleroderma (SSC) associated interstitial lung disease (ILD).  Author URL.
Adamali HI, Stock C, Lindahl GE, Leoni-Garcia P, Russell A-M, Molyneaux PL, Wells A, Renzoni E, Maher T (2012). The Effect of Telomere Length in Idiopathic Pulmonary Fibrosis. C109. EFFECTS OF SENESCENCE AND MANIFESTATIONS OF AGING IN THE LUNG.
Saini G, Jenkins G, Mckeever T, Simpson J, Hubbard R, Johnson S, Braybrooke R, Russell A-M, Meakin G, Sweeney L, et al (2012). The PROFILE Study: a Prospective Study of Fibrosis in Lung Endpoints to Discover and Qualify Biomarkers for Use in Clinical Trials. C103. PATHOGENESIS, BIOMARKERS, AND RISK FACTORS FOR INTERSTITIAL LUNG DISEASE: FROM BENCH TO BEDSIDE.
Molyneaux PL, Russell AM, Cox MJ, Moffatt MF, Cookson WO, Maher TM (2012). The Respiratory Microbiome in Idiopathic Pulmonary Fibrosis. C103. PATHOGENESIS, BIOMARKERS, AND RISK FACTORS FOR INTERSTITIAL LUNG DISEASE: FROM BENCH TO BEDSIDE.
Yorke J, Moosavi SH, Russell AM, Jones PW (2010). Psychological Distress is Associated with Greater Breathlessness Severity. C55. ADVANCES IN DYSPNEA MEASUREMENT.
Yorke J, Moosavi SH, Russell AM, Jones PW (2009). Does Slight Variation in Situational Wording on Breathlessness Questionnaires Make a Difference?.  Author URL.
Yorke J, Moosavi SH, Russell AM, Jones PW (2009). Validity and Reliability of the Dyspnoea-12.  Author URL.

Back to top

External Engagement and Impact

Awards

Professional:

  • ILD Interdisciplinary Network 2023 Innovation in Digital Technology Award
  • American Thoracic Society Fellow 2020 School 

Internal:

  • University of Exeter Above and Beyond Award 2023

Patient & Public Involvement:

  • Irish Healthcare Awards 2019 Patient Organisation Project of the Year. Commendation for World Café Event on Palliative Care and Planning for the Future (ILFA)

Committee/panel activities

European Respiratory Society:

  • College of Experts member
  • Taskforce member
    • ERS TF2022-16 - Management of patients with IPF &  LungCancer 
    • ERS TF-2021-08 Guideline on symptom management in advanced lung disease 
  • Reviewer - abstracts / awards & CTF programme 

Advancing ILD Research (AIR Europe): Faculty member 

JLA: Progressive Pulmonary Fibrosis research priority setting partnership (PPF PSP) 2020/2

         https://www.jla.nihr.ac.uk/priority-setting-partnerships/progressive-pulmonary-fibrosis/ 

PPIE:

  • European Pulmonary Fibrosis Federation EU-IPFF Scientific Advisory board member 
  • Exeter Patients in Collaboration for Pulmonary Fibrosis Research (EPIC PF) group member

Terms of office served

  • ILD Interdisciplinary National Network Chair-elect: 2017 – 2019
  • American Thoracic Society Program Committee Chair-elect: 2018 – 2019
  • American Thoracic Society  Members in Transition and Training Committee 2017-2018
  • American Thoracic Society Awards Committee member 2017-19

External positions

ILD Podcast Series Host: 

ILD Academy Spotlight Podcasts | Podcast on Spotify

ILD Academy Spotlight Podcasts on Apple Podcasts

The ILD Academy ‘Spotlight Podcasts’  2022 feature prominent members of the UK and Ireland ILD community. Sponsored by Boehringer Ingelheim the podcasts aim to shine a spotlight on the great work being done around the country, and break down some of the challenges facing us in delivering excellent care to our patients.


Invited lectures

Key selected contemporary talks

  1. 'Managing wellbeing in ILD'. In: Mini Short Course: Part 1 Supportive Therapies in Interstitial Lung Disease: It’s Not Just About Anti-fibrotics: British Thoracic Society Summer Meeting June 2023
  2. 'Creating a Thinking Environment: A novel approach to successful mentoring'. In: ILD Interdisciplinary Network National Conference, Birmingham / UK Oct 2022
  3.  'ILD: Progressive fibrosis and Anti-fibrotic Treatment', In: Respiratory Professional Care, NEC, Birmingham /UK Oct 2022
  4. 'Which follow-up strategies relate to cognitive, psychological and quality-of-life consequences?' In: Clinical case discussion: ERS statement on long COVID-19 follow-up. European Respiratory Society Webinar  https://www.ersnet.org/ers-respiratory-channel/clinical-case-discussion-ers-statement-on-long-covid-19-follow-up/  Apr 2022
  5.  “Home spirometry to support self-management of ILD” In: Role of home spirometry and wearable devices in digital health Symposium; The Australia & New Zealand Society of Respiratory Science and The Thoracic Society of Australia and New Zealand (ANZSRS/TSANZ), Annual Scientific Meeting for Leaders in Lung Health & Respiratory Science. Apr 2022
  6. 'Patient-reported measures in ILD'. In: Respiratory Nurses SIG Symposium TSANZ Annual Scientific Meeting Apr 2022
  7. 'CTD-ILD: what is really relevant for our patients?' In:  Prof. Dr. Jules van den Bosch Symposium VII, St. Antonius ILD Centre, Nieuwegein. Netherlands Jan 2019
  8. 'Palliative care and end of life management for IPF patients'. In: Fergus Goodbody Memorial Lecture & Respiratory Masterclass; Royal College of Physicians Ireland  https://www.youtube.com/watch?v=Tcy3j5H7HMg March 2018

Key selected contemporary sessions Chaired: 

  • British Thoracic Society Winter Meeting  | London 2022 |  Chair:Spoken Session
  • Advancing IPF Research Autumn Meeting | Basel | Switerland 2022 | Co-Chair Panel Discussion 

Back to top

Office Hours:

Please note my PG teaching day is Tuesday 08:30 - 17:30h

Back to top

Edit Profile